FACS analysis of BAL cell suspensions (Fig. 4E) confirmed that addition of CpG to the N+LT neonatal vaccine abolished BAL eosinophilia (from nearly 8% down to 0.3% SiglecF+ CD11clow CD45+ BAL cells). This evidence concerns the gene PTPRC and Increased total eosinophil count.